瘤微环境响应RNA药物输送系统:用于复杂释放的智能平台
Guihua Wang1,2, Mengxia Zhang2,3, Weiwei Lai1,2
1Institute of Pharmacy & Pharmacology, University of South China, Hengyang 421001, China.
Molecular pharmaceutics
|July 26, 2024
概括
本综述探讨了用于RNA基因治疗的瘤微环境响应纳米载体的使用. 这些先进的系统改善了药物输送,提高了癌症治疗的有效性和安全性.
科学领域:
- 在瘤学瘤学.
- 纳米技术 纳米技术
- 基因治疗 基因治疗
背景情况:
- 癌症治疗面临抗药性挑战,需要新的治疗策略.
- 核糖核酸 (RNA) 基因疗法通过调节基因表达来治疗癌症,但面临着传递障碍.
- 瘤微环境 (TME) 具有独特的特征,可以用于向药物输送.
研究的目的:
- 审查TME的异常成分及其在瘤存活中的作用.
- 讨论基于RNA的癌症药物的治疗潜力和机制.
- 突出TME响应纳米载体的发展和优势,用于癌症治疗中的RNA输送.
主要方法:
- 讨论TME特征:酸性,缺氧,酶过度表达,谷氨 (GSH) 和活性氧物种 (ROS).
- 对治疗性RNA作用和癌症的潜在机制的审查.
- 对用于RNA药物输送的TME响应纳米载体系统的最新进展进行分析.
主要成果:
- 对TME敏感的纳米载体显示出有效的瘤向和降低毒性.
- 这些系统克服了RNA的薄膜透性和稳定性问题.
- 智能药物输送系统可以利用TME功能来改善治疗结果.
结论:
- 响应TME的纳米载体为改善癌症治疗中的RNA基因疗法的疗效提供了一个有希望的策略.
- 优化这些交付向量对于克服当前的局限性至关重要.
- 在这个领域进行进一步的研究可以带来更安全,更实用的癌症治疗选择.
相关概念视频
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


